Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Gliatech (GLIA) -- Ignore unavailable to you. Want to Upgrade?

To: Asymmetric who wrote (649)	2/23/1999 1:15:00 AM
From: scaram(o)uche	Read Replies (2) \| Respond to of 2001

Peter: Annualizing forward from the last quarter, which is of course an absurd buy fun activity, you just sold calls while GLIA is selling at a PE of 67. That, after a first quarter of sales in the U.S. and after seeing penetration at a rate that surprised everyone. Janssen renewed, working on preclinical leads. Japan. New distributors for much of Europe. Pivotal -P trials going. Upfront for 2331 and H3r program outstanding. Lotsa punch in this business plan. Picture an upfront for only a given geography (excluding the U.S.) or for only a given indication. Oesterling has taken the company, with minimal dilution, to a point where they can play at tables with higher minimums. One other thing.... no sales force..... the Adcons are portable. Good luck! Rick